Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Resverlogix Corp T.RVX

Alternate Symbol(s):  RVXCF

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.


TSX:RVX - Post by User

Bullboard Posts
Next >>
Post by G1945Von Jul 28, 2020 6:07pm
196 Views
Post# 31333842

Resverlogix Announces Extension of its Filing

Resverlogix Announces Extension of its Filing Resverlogix Announces Extension of its Filing Calendar Based on Continuous Disclosure Exemption

CALGARY, Alberta, July 28, 2020 (GLOBE NEWSWIRE) -- Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) announces that it intends to rely on blanket exemptions issued by provincial securities commissions due to the COVID-19 outbreak that permit the Company to extend the filing deadline of certain continuous disclosure documents for a period of up to 45 days.

The Company intends to rely on the exemptive relief to extend the date of filing of its annual financial statements for the year ended April 30, 2020 and related management's discussion and analysis pursuant to National Instrument 51-102 (collectively, the "Annual Filings").

Resverlogix expects to rely on the exemption to file the Annual Filings on or before September 11, 2020, and notes that management and other insiders are subject to a trading black-out policy that reflects the principles in section 9 of National Policy 11-207.

Resverlogix confirms there have been no undisclosed material business developments since the filing on March 13, 2020 of the Company’s condensed interim consolidated financial statements and associated management's discussion and analysis for the nine-month period ended January 31, 2020 that have not been otherwise disclosed by Resverlogix by way of news release.

G1945V

Bullboard Posts
Next >>